



College of Homeopaths of Ontario
www.collegeofhomeopaths.com

October 2, 2026

Catherine Ngando Edimo, Clerk of the Committee
Standing Committee on Health
Sixth Floor, 131 Queen Street
House of Commons
Ottawa ON K1A 0A6

By e-mail to HESA@parl.gc.ca

Subject: Support for Bill C-224, An Act to Amend the *Food and Drugs Act* (natural health products)

Members of the Standing Committee on Health,

I am writing in support of Bill C-224, *An Act to amend the Food and Drugs Act (natural health products)*.

Bill C-224 would clarify that natural health products are not therapeutic products under the *Food and Drugs Act* and should not be subject to the same regulatory monitoring regime as pharmaceuticals. The bill recognizes the longstanding distinction between natural health products and higher-risk therapeutic products and promotes a more proportionate, risk-based approach to regulation.

Natural health products already operate within a dedicated regulatory framework that includes licensing, manufacturing, labelling, quality, and safety requirements. Subjecting these products to regulatory measures designed for pharmaceuticals creates unnecessary compliance burdens without demonstrating a corresponding public health benefit.

As discussed in the [College of Homeopaths of Ontario's submission to Health Canada regarding proposed Natural Health Product Compounding and Raw Materials Policies](#), excessive federal oversight risks restricting access to low-risk natural health products, limiting patient choice, and creating barriers for regulated healthcare practitioners who rely on these products in the course of providing care. The submission further notes that public protection is achieved through existing federal product standards and provincial professional regulation, and that regulatory requirements should be proportionate to actual risk.

Bill C-224 supports consumer access, regulatory clarity, and patient choice while preserving Health Canada's authority to regulate product quality and safety. It provides an appropriate legislative balance between public protection and access to natural health products that millions of Canadians rely upon.

For these reasons, I encourage the Committee to support Bill C-224.

Respectfully submitted,

A handwritten signature in grey ink, appearing to read 'Basil Ziv'.

Basil Ziv
Registrar & CEO
College of Homeopaths of Ontario

Supporting References

1. Bill C-224, *An Act to amend the Food and Drugs Act (natural health products)*, First Reading, September 18, 2025.
2. [CHO Response to Health Canada proposed NHP Compounding and Raw Materials Policy](#), College of Homeopaths of Ontario, July 8, 2026. The submission argues that restrictions on access to natural health products should be proportionate to risk and should not unnecessarily interfere with patient access or regulated professional practice.